Lenacapavir
Sold as Lenacapavir gilead
No structure available
This product's active ingredient could not be matched to a single known compound.
Background
Registration
- Applicants
- 1
- Registrations
- 2
Applicants and registrations
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Lenacapavir 464 MG solution for injection gilead EACH VIAL CONTAINS: LENACAPAVIR SODIUM EQUIVALENT TO: LENACAPAVIR 463,5 mg | 464 mgSolution for injection | 60081060/20.2.8/0810Approved 21 October 2025 | Registered | Not determined | PIPIL |
| Lenacapavir 300 MG tablet gilead EACH TABLET CONTAINS: LENACAPAVIR SODIUM EQUIVALENT TO: LENACAPAVIR 300,0 mg | 300 mgFilm-coated tablet | 60081160/20.2.8/0811Approved 14 October 2025 | Registered | Not determined | PIPIL |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.